Brown & Brown, Inc. (BRO) Stock Price & How to Invest

Brown & Brown is a Daytona Beach, Florida based insurance intermediary that connects businesses and individuals with insurance carriers, collecting commissions and fees instead of taking underwriting risk on its own balance sheet. It operates through two reportable segments after a 2025 reorganization, Retail and Specialty Distribution, spanning property and casualty, employee benefits, programs, and wholesale brokerage. The business is fee-based and capital-light, which historically produced high margins, strong free cash flow, and decades of dividend increases, and management has grown for years by acquiring smaller agencies and folding them into its decentralized model.

The current investment picture centers on two things: the roughly $9.8 billion Accession Risk Management Group (RSC) acquisition completed in August 2025, its largest ever, and a shift in the underlying insurance market from hard (rising premiums) to soft (flat to falling premiums). Accession pushed 2025 total revenue up about 23% to over $5.9 billion but also added meaningful debt and integration work, while organic growth (revenue excluding acquisitions) has decelerated from double digits to the mid single digits as pricing softens. The result is a company with a strong long-term franchise trading at a premium multiple, where the near-term question is whether acquisitions and margin discipline can offset slower organic momentum.

The first half of 2026 showed Accession in the numbers. Revenue was about $1.9 billion in the first quarter (a seasonally strong period for contingent commissions) and about $1.68 billion in the second, up roughly 32% year over year, with trailing twelve-month revenue reaching about $6.66 billion and net income about $1.19 billion. Adjusted EPS of $1.07 in the second quarter matched the consensus exactly, after small beats in the three prior quarters. Debt stands near $8.07 billion against about $918 million of cash.

The stock has not followed revenue upward. As of October 16, 2026 it closed at about $68.68, down about 11.5% year to date and 21% over one year, within a 52-week range of about $53.81 to $90.46, though it has bounced about 5.6% over the past month. In mid-October Keefe Bruyette & Woods upgraded the shares to Outperform with a $77 target and TD Cowen started coverage at Buy with an $82 target, while Bank of America cut its target to $81 from $87 and Wells Fargo trimmed to $68. Brown & Brown also expanded its preferred-partner relationship with Marcus & Millichap into Canada. Third-quarter results are due October 26, 2026, with consensus EPS of about $1.08 on about $1.76 billion of revenue.

The dominant near-term risk is a softening insurance-rate environment: organic growth slowed toward the mid single digits (around 3.6% in a recent quarter versus roughly 10% a year earlier) as premium rates flatten or fall across property, casualty, cyber, and executive lines, which pressures commission-based revenue. Integration risk from the large debt-funded Accession deal is significant, and the added leverage (about $8.07 billion of debt against roughly $918 million of cash) reduces financial flexibility if results disappoint. The stock trades at a premium valuation, so any further deceleration in organic growth or margin can drive sharp multiple compression, as the stock's roughly 21% decline over the year to October 2026 showed. Falling interest rates would reduce income on fiduciary balances, and a downturn in carrier profitability could shrink contingent commissions. Longer term, consolidation among larger rivals and questions about AI disrupting distribution add competitive uncertainty.

18 analysts publish price targets on BRO, averaging $74.67 against a $69.40 price as of October 2026, or +7.6%. The published targets run from $55.00 to $90.00, a moderate spread, and the ratings split 7 buy, 13 hold, 1 sell. Over the last six months there have been 5 raises and 6 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full BRO forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Brown & Brown, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Acquisition-led compounding. Brown & Brown has grown for decades by buying independent agencies and brokerages, completing dozens of deals a year, most recently the roughly $9.8 billion Accession acquisition that added over 5,000 professionals and about $1.7 billion of pro forma revenue. The most optimistic published target, $90.00, assumes this works close to its best case.

The case against. The dominant near-term risk is a softening insurance-rate environment: organic growth slowed toward the mid single digits (around 3.6% in a recent quarter versus roughly 10% a year earlier) as premium rates flatten or fall across property, casualty, cyber, and executive lines, which pressures commission-based revenue. The most pessimistic target, $55.00, is roughly what BRO is worth if this bites instead.

Read the full bull and bear case on BRO, including what would have to change to break either one. Walnut is not an investment adviser.

Yes. Brown & Brown, Inc. (BRO) has had one share split in the last 10 years:

• 2:1 on March 29, 2018, so every share held became 2 shares.

A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of BRO the day before the 2:1 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.

Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Brown & Brown, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$6.66 billion; Q2 2026 revenue ~$1.68 billion, up ~32% YoY (mostly Accession)
• Net income (TTM): ~$1.19 billion; net margin ~18%
• Q2 2026 EPS: ~$1.07 adjusted, in line with ~$1.07 consensus
• Market cap: ~$23 billion at ~$68.68 (Oct 16, 2026)
• P/E: ~21.7x trailing, ~14.2x forward
• Dividend yield: ~1% (~$0.66/yr), ~20% payout
• Leverage: ~$8.07 billion debt, ~$918 million cash
• Next report: Q3 2026 on Oct 26, 2026; consensus EPS ~$1.08 on ~$1.76 billion revenue

As of mid-October 2026 BRO traded near $69 with a market cap around $23 billion, a trailing P/E in the low 20s and a forward P/E near 14. The stock is down about 21% over a year even as reported revenue grew sharply, because that growth came from the Accession acquisition rather than organic momentum, and analysts on average rate it Hold with a mean target near $74.67. The forward multiple sits well below the trailing one because analysts expect earnings accretion from Accession, with estimates of about $4.48 of EPS for 2026 and $4.83 for 2027.

Other names that sit close to BRO: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get BRO exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so BRO sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where BRO fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

BRO is a high-quality, acquisitive insurance broker whose long compounding record is being tested by slowing organic growth and a large debt-funded deal, so the debate is about the price paid for that durability. That price has come down: at about $68.68 in October 2026 the stock sits roughly a quarter below its 52-week high and near 14 times forward earnings, and several analysts turned more constructive in October ahead of the October 26 report.

Whether BRO is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is BRO a buy or a sell?, and where the stock could go from here in the BRO stock forecast.

For income investors, whether BRO pays a dividend and how the payout looks is covered in does BRO pay a dividend? And to weigh BRO against a peer, read the full side-by-side comparisons: BRO vs MRSH and BRO vs AON.